ArticleBMC cancer2026
Association of immunohistochemistry-based molecular subtypes with adnexal involvement in endometrial cancer.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAdnexal involvement in endometrial cancer is traditionally regarded as an anatomical spread pattern within FIGO stage IIIA; however, its biological heterogeneity remains incompletely understood. The 2023 FIGO staging system distinguishes between favorable "synchronous" ovarian involvement (stage IA3) and true metastatic spread to the ovary (stage IIIA1), highlighting the biological heterogeneity of adnexal involvement. This study aimed to investigate the association between immunohistochemistry (IHC)-based molecular subtypes and adnexal involvement, together with relevant clinicopathological factors.
methodsThis retrospective, single-center study included patients with surgically staged endometrial cancer. Tumors were classified into p53-abnormal, mismatch repair-deficient (MMRd) and non-specific molecular profile (NSMP) subtypes based on immunohistochemistry. Associations between adnexal involvement and molecular subtypes, preoperative serum CA-125 levels, lymphovascular space invasion (LVSI) and other clinicopathological variables were analyzed.
resultsAmong 661 patients, adnexal involvement was identified in 3.8% (n = 25) and varied significantly across molecular subtypes (p < 0.001). In multivariable analysis, p53-abnormal tumors showed a strong independent association with adnexal involvement (aOR 5.15, 95% CI 1.87-14.19, p = 0.001), whereas NSMP tumors were associated with lower risk. Elevated preoperative CA-125 levels (aOR 1.01, p < 0.001) and the presence of LVSI (aOR 6.62, p < 0.001) were also independent predictors.
conclusionIHC-based molecular subtypes are significantly associated with adnexal involvement in endometrial cancer. Integrating molecular classification with clinicopathological factors may enhance more individualized surgical planning, particularly regarding ovarian preservation decisions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.